Cargando…

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study

INTRODUCTION: To compare the effect of dulaglutide and liraglutide on oxidative stress and endothelial function in patients with type 2 diabetes mellitus (T2DM). METHODS: Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagaike, Hiroe, Ohara, Makoto, Kohata, Yo, Hiromura, Munenori, Tomoyasu, Masako, Takada, Michiya, Yamamoto, Takeshi, Hayashi, Toshiyuki, Fukui, Tomoyasu, Hirano, Tsutomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349295/ https://www.ncbi.nlm.nih.gov/pubmed/30612316 http://dx.doi.org/10.1007/s13300-018-0560-8

Ejemplares similares

Association of glucose and blood pressure variability on oxidative stress in patients with type 2 diabetes mellitus and hypertension: a cross-sectional study
por: Ohara, Makoto, et al.
Publicado: (2019)

Pancreatic fat accumulation evaluated by multidetector computed tomography in patients with type 2 diabetes
por: Fukase, Ayako, et al.
Publicado: (2020)

The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
por: Kushima, Hideki, et al.
Publicado: (2017)

Association of Hemoglobin A1c, 1,5-Anhydro-d-Glucitol and Glycated Albumin with Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study
por: Kohata, Yo, et al.
Publicado: (2020)

Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes
por: Takehana, Nobuaki, et al.
Publicado: (2023)

Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes
por: Fujikawa, Tomoki, et al.
Publicado: (2021)

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Analysis of pancreatic volume in acute‐onset, slowly‐progressive and fulminant type 1 diabetes in a Japanese population
por: Sasamori, Hiroto, et al.
Publicado: (2018)

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes
por: Ito, Rika, et al.
Publicado: (2015)

Circulating anti‐glutamic acid decarboxylase‐65 antibody titers are positively associated with the capacity of insulin secretion in acute‐onset type 1 diabetes with short duration in a Japanese population
por: Yamamura, So, et al.
Publicado: (2019)

A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression
por: Terasaki, Michishige, et al.
Publicado: (2020)

Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
por: Mori, Yusaku, et al.
Publicado: (2019)

Anti-inflammatory and atheroprotective properties of glucagon
por: Osaka, Naoya, et al.
Publicado: (2020)

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
por: Hirano, Tsutomu, et al.
Publicado: (2023)

Very rare case of Graves’ disease with resistance to methimazole: a case report and literature review
por: Mori, Yusaku, et al.
Publicado: (2021)

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
por: Osaka, Naoya, et al.
Publicado: (2022)

Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2
por: Hiromura, Munenori, et al.
Publicado: (2022)

AGE-RAGE Axis Stimulates Oxidized LDL Uptake into Macrophages through Cyclin-Dependent Kinase 5-CD36 Pathway via Oxidative Stress Generation
por: Yashima, Hironori, et al.
Publicado: (2020)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
por: Su, Yu, et al.
Publicado: (2023)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
por: Terasaki, Michishige, et al.
Publicado: (2017)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Type 1 diabetes patients have lower strength in femoral bone determined by quantitative computed tomography: A cross-sectional study
por: Ishikawa, Koji, et al.
Publicado: (2015)

Pheochromocytoma presenting with severe hyperglycemia and metabolic acidosis following intra-articular glucocorticoid administration: a case report
por: Tomoyasu, Masako, et al.
Publicado: (2019)

Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes
por: Hayashi, Toshiyuki, et al.
Publicado: (2023)

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
por: Tanaka, Kenichi, et al.
Publicado: (2022)

Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
por: Terasaki, Michishige, et al.
Publicado: (2021)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus
por: Taheri, Saeed, et al.
Publicado: (2019)

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
por: Du, Juan, et al.
Publicado: (2023)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
por: Terasaki, Michishige, et al.
Publicado: (2015)

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
por: Chang, Kai-Cheng, et al.
Publicado: (2020)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
por: Boye, Kristina S., et al.
Publicado: (2020)

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
por: Jain, Akshay B., et al.
Publicado: (2020)

Nesfatin-1 suppresses peripheral arterial remodeling without elevating blood pressure in mice
por: Mori, Yusaku, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n7f1s4j73lsnc5fpoj658uc27p